Cassiopea Announces Positive Phase 2 Results For Breezula
Things are heating up.
Cassiopea SpA issued a press release today announcing “very positive” interim analysis phase 2 results for Breezula in the treatment of androgenic alopecia. Breezula is a topical anti-androgen and also known as Clascoterone.
Here are some significant details I found while reading the release:
- The trial comprises 404 subjects and is still ongoing (12 months total)
- Trial subjects apply Clascoterone twice daily
- 4 different concentrations of Clascoterone being trialed (2.5%, 5%, 7.5% BID, 7.5% QD)
- Statistically significant changes were observed in all treatment groups receiving Clascoterone
- Cassiopea mentions that these results halfway through the trial are comparable to the twelve month results of oral Propecia
- Cassiopea is planning for a proof of concept trial for women and also a phase 3 trial for men
All of the details from the press release can be found here.
If Breezula’s efficacy continues to improve over the next 6 months Cassiopea will really have a winner on its hands. Also, if the drug is approved clinically, it would become the first topical anti-androgen for androgenic alopecia. This would surely be a useful remedy for a great number of physicians and patients who are seeking additional solutions to halt hair loss.
Posted in Breezula
I wonder whether 10% would be even more effective ?
If a bald man (Noorwod 6. or 7.) suffers from androgenetic alopecia for more than 15 years, is Breezula able to regrow the hair follicles or only stops the additional hair losing?
Now we just need it to get released. Things are looking better and better for future treatments.
Estimated Release: 2021 🙁
Wish there was something I could do to keep my hair in the meantime. Finasteride gave me bad sides and minoxidil has lost its effectiveness for me
Very good
6 months in and is comparable to a year of Propecia is not the news I was hoping for but at least it’s something.
Yup, it’s best to count the blessings.
That’s not good news to you? Hmm
A couple of things to note:
–reading the press release, it is only the highest dose that exceeded the efficiency of finasteride (7.5%). Makes you think that going to a higher concerntration would be even better.
–The same company recently released the results of a phase 3 trial of the same drug for treating acne, but at 1% concentration. (See here: http://www.cassiopea.com/news-and-media/press-releases/yr-2018/180710.aspx). This caused a big increase in their stock price. This acne treatement should be available a year or two earlier you would think, perhaps 2020 instead of 2022. (Just guessing on the dates). I don’t see why you couldn’t use the acne version on your hair. 🙂
Indeed shouldn’t roacutane also work for baldness?